YOLFTbeta
AmCad BioMed Corporation

AmCad BioMed Corporation

4188 · TWO · Healthcare / Medical Devices

13.95UYU+0.55 (+4.10%)

Price History

Full chart

Market Stats

Previous Close13.40
Open13.50
Day Range13.20 – 14.70
52-Week Range9.06 – 17.65
Volume293.96K
Market Cap892.99M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.83
Dividend Yield0.00%
Beta0.39
50-Day Avg12.54
200-Day Avg12.49

About

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMs. Yi-Li Lee
  • Employees0
  • HeadquartersNo. 167 Fuxing North Road, Taipei, Taiwan, 104, Ireland
  • Websitehttps://www.amcad.com.tw

Leadership

  • Ms. Yi-Li LeeChairman, President & Manager
  • Ann ChenFinancial Officer
  • Zhao Ming ChenAccounting Supervisor
  • Mr. Zhenggang ChenChief R&D Officer

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue63.94M85.79M61.63M65.26M53.10M30.44M
Growth (%)-+34.17%-28.16%+5.88%-18.62%-42.69%
Cost of Revenue21.61M25.13M23.58M24.23M20.17M20.41M
Gross Profit42.33M60.66M38.05M41.02M32.93M10.02M
Gross Margin66.21%70.71%61.73%62.87%62.02%32.93%
Operating Expense85.17M87.51M92.32M84.05M97.60M97.98M
Operating Income-42.84M-26.84M-54.28M-43.03M-64.66M-87.95M
Operating Margin-66.99%-31.29%-88.07%-65.93%-121.77%-288.97%
EBITDA-23.17M-8.56M-36.65M-25.56M-34.41M-55.52M
EBITDA Margin-36.24%-9.98%-59.47%-39.17%-64.80%-182.40%
Net Income-35.44M-25.54M-53.49M-45.31M-50.58M-55.72M
Net Income Margin-55.43%-29.77%-86.79%-69.44%-95.24%-183.06%
R&D49.42M50.95M54.00M44.12M43.78M47.11M
R&D as % of Total Revenue77.29%59.39%87.62%67.61%82.45%154.78%
Interest Expense91.00K144.00K117.00K123.00K180.00K88.00K
Interest Expense % of Total Revenue0.14%0.17%0.19%0.19%0.34%0.29%

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-615.75M553.86M512.65M694.87M622.70M
Total Liabilities-36.72M34.08M34.70M31.16M21.88M
Total Equity-482.98M424.58M380.58M568.65M521.42M
Cash-58.51M47.04M29.66M17.76M24.60M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--50.05M-38.97M-34.19M-41.60M-51.85M-47.06M
Financing Cash Flow--5.02M-11.35M-4.42M-3.10M--
Capital Expenditure0320.00K2.33M614.00K293.00K3.05M700.00K
Free Cash Flow--50.37M-41.30M-34.81M-41.89M-54.90M-47.76M
FCF to OCF-100.64%105.99%101.80%100.70%105.88%101.49%

Earnings

Report DateMar 31, 2015Jul 29, 2015
EPS Estimate-0.28-0.37
EPS Actual-0.530.00
Surprise-89.29%100.00%
Timing-Pre-market

Key Statistics & Ratios

Market Cap892.99M
Enterprise Value611.95M
Trailing P/E0.00
Forward P/E0.00
Price / Sales31.22
Price / Book1.82
EPS-0.83
Book Value8.14
Revenue (TTM)28.60M
Gross Profit (TTM)10.33M
EBITDA-75.81M
Profit Margin-184.10%
Operating Margin-334.67%
Return on Equity-11.18%
Return on Assets-8.61%
Shares Outstanding63.33M
Shares Float31.63M
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%